Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 1/20 | 0.42 |
| ▸ | DUT | P33316 | 3/20 | 0.41 |
| ▸ | DDB1 | Q16531 | 5/20 | 0.41 |
| ▸ | CRBN | Q96SW2 | 5/20 | 0.41 |
| ▸ | HTR6 | P50406 | 2/20 | 0.41 |
| ▸ | PKM | P14618 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | F2 | P00734 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | PKLR | P30613 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | PGR | P06401 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20204875 | 0.93 | HTR6 (0.42) | DDB1CRBNHTR6PKMALDH1A1 | |
| SCHEMBL21536738 | 0.90 | DUT (0.42) | ROCK2DUTDDB1CRBNPKM | |
| SCHEMBL21536688 | 0.87 | DDB1 (0.44) | ROCK2DUTDDB1CRBNALDH1A1 | |
| SCHEMBL20204818 | 0.85 | DUT (0.44) | ROCK2DUTDDB1CRBNHTR6 | |
| SCHEMBL21536067 | 0.83 | DDB1 (0.46) | DUTDDB1CRBNPKMALDH1A1 | |
| SCHEMBL26029515 | 0.80 | DUT (0.41) | ROCK2DUTPKMALDH1A1F2 | |
| SCHEMBL21536686 | 0.80 | DDB1 (0.43) | DUTDDB1CRBNHTR6PKM | |
| SCHEMBL21536616 | 0.77 | DUT (0.45) | ROCK2DUTALDH1A1USP2LMNA | |
| SCHEMBL21536612 | 0.77 | DUT (0.56) | DUTF2PGR | |
| SCHEMBL21536613 | 0.75 | DUT (0.45) | ROCK2DUTDDB1CRBNF2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11168059-B2 | Amino sulfonyl compounds | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2021-11-09 | — | — | US | disclosed |
| US-20190330158-A1 | AMINO SULFONYL COMPOUNDS | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2019-10-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11168059-B2 | Amino sulfonyl compounds | DPYD, DNPEP, DUT | ROCK2 4782/4885DUT 3/4885DDB1 33/4885 |
| US-20190330158-A1 | AMINO SULFONYL COMPOUNDS | DPYD, DNPEP, DUT | ROCK2 4782/4885DUT 3/4885DDB1 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.